|
Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery
RECRUITINGSponsored by Liaoning Cancer Hospital & Institute
Actively Recruiting
SponsorLiaoning Cancer Hospital & Institute
Started2024-03-21
Est. completion2025-09
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06109454
Summary
This study is a multicenter, prospective, and observational clinical study aimed at exploring whether the 3-year DFS in the Huaier group is not inferior to the control group receiving standard platinum dual-drug chemotherapy.
Eligibility
Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria: * 18 years old ≤ age ≤ 75, regardless of gender. * Confirmed as non-small cell lung cancer by histopathology, with pathological staging of stage Ⅱ-ⅢA. * Received radical R0 resection of lung cancer within 2 months before enrollment, and did not receive any postoperative adjuvant therapy or preoperative neoadjuvant therapy. * ECOG(Eastern Cooperative Oncology Group)score:0-2. * The patient voluntarily participated in the study, agreed to cooperate with the researcher for data collection, and signed an informed consent form. Exclusion Criteria: * Known to be allergic to the components of Huaier granules or avoid or use Huaier granules with caution (Huaier group). * Those who have difficulty swallowing, complete or incomplete gastrointestinal obstruction, active gastrointestinal bleeding, perforation, and other causes of difficulty in taking oral medication. * Non-small cell lung cancer patients who plan to receive targeted therapy, immunotherapy, chemotherapy combined with immunotherapy, radiotherapy, synchronous radiotherapy and chemotherapy during the study period. * The patient has a history of other new malignant tumors within 5 years. * The expected survival time of the patient is less than half a year. * Surgical complications that have not recovered or are accompanied by severe infections after radical resection of lung cancer. * Pregnant or lactating women or planned pregnancy preparation. * The patient has received other traditional Chinese patent medicines and simple preparations with anti-tumor effect in the past one month (including but not limited to compound cantharidin capsule, cinobufagin capsule, Kangai injection, Brucea javanica injection, etc., the specific instructions shall prevail). * The patient suffers from severe mental illness or other reasons that the researcher deems unsuitable to participate in this study.
Conditions3
CancerLung CancerNon Small Cell Lung Cancer
Interventions1
Related trials
- Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer — Fudan University
- Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy — Fudan University
- The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer — Xi'an Jiaotong University
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorLiaoning Cancer Hospital & Institute
Started2024-03-21
Est. completion2025-09
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06109454